Opthea Limited (OPT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South Yarra, VIC, Australia. The current CEO is Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,.
OPT has IPO date of 2020-10-16, 33 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $4.24B.
Opthea Limited is a clinical-stage biopharmaceutical company based in South Yarra, Australia, focused on developing therapies for eye diseases. The company's pipeline is built on intellectual property targeting VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions involving abnormal blood and lymphatic vessel growth and vascular leakage. Its lead candidate, OPT-302, is a soluble VEGFR-3 inhibitor in clinical development for wet age-related macular degeneration and diabetic macular edema, designed to work alongside VEGF-A inhibitors for improved efficacy in retinal diseases.
